Eradicating the Roots of Relapse
At Cellyxa Therapeutics, our mission is to revolutionize oncology by targeting the root biological causes of cancer relapse. We are a clinical-stage bio-pharmaceutical company engineered to go beyond remission and deliver definitive, durable patient outcomes.
The Philosophy
The current standard of care in oncology focuses heavily on reducing tumor bulk mass. However, we recognize that true curative potential lies in outsmarting cancer's adaptability. Tumors survive by hijacking developmental processes to create dormant, highly resilient cancer stem cells. These are the underlying drivers of drug resistance and aggressive metastasis.
Our Approach
We are pioneering precision therapeutics that selectively disrupt the molecular drivers of stemness. By dismantling the biology of recurrence at its source, we are shifting the paradigm from managing disease progression to actively eradicating the "seeds" of relapse.
Our Foundation
Cellyxa is built on a symbiotic foundation of rigorous, peer-reviewed academic research. We combine world-class medical oncology and molecular pharmacology expertise with a proven track record of navigating complex biopharma markets. This end-to-end capability ensures that our innovative, first-in-class assets are strategically positioned to move swiftly from the laboratory to the clinic, and ultimately, to the patients who need them most.